Trial Profile
Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in Inflammatory Bowel Disease Patients Treated With Vedolizumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Jan 2020
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary) ; Hepatitis B vaccine; Influenza virus vaccine; Influenza virus vaccine (Afluria); Pneumococcal 13-valent CRM197 vaccine conjugate; Pneumococcal vaccine
- Indications Inflammatory bowel diseases
- Focus Pharmacodynamics
- 27 Dec 2019 Status changed from active, no longer recruiting to completed.
- 24 Jul 2019 Status changed from recruiting to active, no longer recruiting.
- 12 Jul 2018 Planned End Date changed from 30 Jun 2018 to 31 Dec 2019.